These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9150488)

  • 1. Rapid carcinogenicity testing system with transgenic mice harboring human prototype c-HRAS gene.
    Yamamoto S; Hayashi Y; Mitsumori K; Nomura T
    Lab Anim Sci; 1997 Apr; 47(2):121-6. PubMed ID: 9150488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid induction of more malignant tumors by various genotoxic carcinogens in transgenic mice harboring a human prototype c-Ha-ras gene than in control non-transgenic mice.
    Yamamoto S; Mitsumori K; Kodama Y; Matsunuma N; Manabe S; Okamiya H; Suzuki H; Fukuda T; Sakamaki Y; Sunaga M; Nomura G; Hioki K; Wakana S; Nomura T; Hayashi Y
    Carcinogenesis; 1996 Nov; 17(11):2455-61. PubMed ID: 8968063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility of transgenic mice carrying human prototype c-Ha-ras gene in a short-term carcinogenicity study of vinyl carbamate and ras gene analyses of the induced tumors.
    Mitsumori K; Wakana S; Yamamoto S; Kodama Y; Yasuhara K; Nomura T; Hayashi Y; Maronpot RR
    Mol Carcinog; 1997 Nov; 20(3):298-307. PubMed ID: 9397190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of transgenic mice carrying the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing.
    Yamamoto S; Urano K; Koizumi H; Wakana S; Hioki K; Mitsumori K; Kurokawa Y; Hayashi Y; Nomura T
    Environ Health Perspect; 1998 Feb; 106 Suppl 1(Suppl 1):57-69. PubMed ID: 9539005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of transgenic mice harboring the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing.
    Yamamoto S; Urano K; Nomura T
    Toxicol Lett; 1998 Dec; 102-103():473-8. PubMed ID: 10022298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of invasive mouse skin carcinomas in transgenic mice with mutations in both H-ras and p53.
    Zhang Z; Yao R; Li J; Wang Y; Boone CW; Lubet RA; You M
    Mol Cancer Res; 2005 Oct; 3(10):563-74. PubMed ID: 16254190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transgene stability and features of rasH2 mice as an animal model for short-term carcinogenicity testing.
    Suemizu H; Muguruma K; Maruyama C; Tomisawa M; Kimura M; Hioki K; Shimozawa N; Ohnishi Y; Tamaoki N; Nomura T
    Mol Carcinog; 2002 May; 34(1):1-9. PubMed ID: 12112317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Tg rasH2 mouse in cancer hazard identification.
    Morton D; Alden CL; Roth AJ; Usui T
    Toxicol Pathol; 2002; 30(1):139-46. PubMed ID: 11890467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interlaboratory comparison of short-term carcinogenicity studies using CB6F1-rasH2 transgenic mice.
    Takaoka M; Sehata S; Maejima T; Imai T; Torii M; Satoh H; Toyosawa K; Tanakamaru ZY; Adachi T; Hisada S; Ueda M; Ogasawara H; Matsumoto M; Kobayashi K; Mutai M; Usui T
    Toxicol Pathol; 2003; 31(2):191-9. PubMed ID: 12696579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CB6F1-rasH2 mouse: overview of available data.
    Usui T; Mutai M; Hisada S; Takoaka M; Soper KA; McCullough B; Alden C
    Toxicol Pathol; 2001; 29 Suppl():90-108. PubMed ID: 11695565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the Xpa-deficient transgenic mouse model for short-term carcinogenicity testing: 9-month studies with haloperidol, reserpine, phenacetin, and D-mannitol.
    Lina BA; Woutersen RA; Bruijntjes JP; van Benthem J; van den Berg JA; Monbaliu J; Thoolen BJ; Beems RB; van Kreijl CF
    Toxicol Pathol; 2004; 32(2):192-201. PubMed ID: 15200157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transgenic mice in carcinogenicity testing.
    Griesemer R; Tennant R
    IARC Sci Publ; 1992; (116):429-36. PubMed ID: 1428092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathological features of spontaneous and induced tumors in transgenic mice carrying a human prototype c-Ha-ras gene used for six-month carcinogenicity studies.
    Mitsumori K; Koizumi H; Nomura T; Yamamoto S
    Toxicol Pathol; 1998; 26(4):520-31. PubMed ID: 9715511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The utility of the K6/ODC transgenic mouse as an alternative short term dermal model for carcinogenicity testing of pharmaceuticals.
    Miller TJ; Honchel R; Espandiari P; Knapton A; Zhang J; Sistare FD; Hanig JP
    Regul Toxicol Pharmacol; 2008 Feb; 50(1):87-97. PubMed ID: 18069108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetically altered mouse models for identifying carcinogens.
    Tennant RW; Stasiewicz S; Mennear J; French JE; Spalding JW
    IARC Sci Publ; 1999; (146):123-50. PubMed ID: 10353386
    [No Abstract]   [Full Text] [Related]  

  • 16. Twenty-six-Week carcinogenicity study of chloroform in CB6F1 rasH2-transgenic mice.
    Sehata S; Maejima T; Watanabe M; Ogata S; Makino T; Tanaka K; Manabe S; Takaoka M
    Toxicol Pathol; 2002; 30(3):328-38. PubMed ID: 12051550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the Emu-pim-1 transgenic mouse model for short-term carcinogenicity testing.
    van Kreijl CF; van der Houven van Oordt CW; Kroese ED; Sørensen IK; Breuer ML; Storer RD
    Toxicol Pathol; 1998; 26(6):750-6. PubMed ID: 9864091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The rasH2 transgenic mouse: nature of the model and mechanistic studies on tumorigenesis.
    Tamaoki N
    Toxicol Pathol; 2001; 29 Suppl():81-9. PubMed ID: 11695564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the carcinogenic potential of clofibrate in the FVB/Tg.AC mouse after dermal application--part II.
    Torrey CE; Wall HG; Campbell JA; Kwanyuen P; Hoivik DJ; Miller RT; Allen JS; Jayo MJ; Selinger K; Santostefano MJ
    Int J Toxicol; 2005; 24(5):327-39. PubMed ID: 16257852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
    Gaylor DW
    Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.